Fresenius SE Total Non-Operating Income/Expense 2016-2024 | FSNUY
Fresenius SE annual/quarterly total non-operating income/expense history and growth rate from 2016 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Fresenius SE total non-operating income/expense for the quarter ending September 30, 2024 was $-0.085B, a 22.21% decline year-over-year.
- Fresenius SE total non-operating income/expense for the twelve months ending September 30, 2024 was $-0.329B, a 47.7% decline year-over-year.
- Fresenius SE annual total non-operating income/expense for 2023 was $-0.463B, a 13.28% decline from 2022.
- Fresenius SE annual total non-operating income/expense for 2022 was $-0.534B, a 10.77% decline from 2021.
- Fresenius SE annual total non-operating income/expense for 2021 was $-0.599B, a 20.47% decline from 2020.
Fresenius SE Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$-463 |
| 2022 |
$-534 |
| 2021 |
$-599 |
| 2020 |
$-753 |
| 2019 |
$-805 |
| 2018 |
$-693 |
| 2017 |
$-736 |
| 2016 |
$-644 |
| 2015 |
$-681 |
Fresenius SE Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-09-30 |
$-85 |
| 2024-06-30 |
$-115 |
| 2024-03-31 |
$-157 |
| 2023-12-31 |
$29 |
| 2023-09-30 |
$-109 |
| 2023-06-30 |
$-201 |
| 2023-03-31 |
$-182 |
| 2022-12-31 |
$-136 |
| 2022-09-30 |
$-142 |
| 2022-06-30 |
$-123 |
| 2022-03-31 |
$-132 |
| 2021-12-31 |
$-139 |
| 2021-09-30 |
$-149 |
| 2021-06-30 |
$-146 |
| 2021-03-31 |
$-165 |
| 2020-12-31 |
$-188 |
| 2020-09-30 |
$-180 |
| 2020-06-30 |
$-184 |
| 2020-03-31 |
$-201 |
| 2019-12-31 |
$-204 |
| 2019-09-30 |
$-191 |
| 2019-06-30 |
$-201 |
| 2019-03-31 |
$-209 |
| 2018-12-31 |
$-158 |
| 2018-09-30 |
$-167 |
| 2018-06-30 |
$-185 |
| 2018-03-31 |
$-183 |
| 2017-12-31 |
$-188 |
| 2017-09-30 |
$-192 |
| 2017-06-30 |
$-189 |
| 2017-03-31 |
$-167 |
| 2016-12-31 |
$-162 |
| 2016-09-30 |
$-157 |
| 2016-06-30 |
$-157 |
| 2016-03-31 |
$-168 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$21.804B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
